Biogen Inc. and partner Eisai Co said their experimental drug lecanemab significantly slowed the disease, making it the first medicine to blunt progression of the most common dementia in a large definitive study
Dublin, Aug. 30, 2022 (GLOBE NEWSWIRE) The "Global Alzheimer's Therapeutics Market Size, Share & Trends Analysis Report by Product (Cholinesterase.
The research team discovered that treatment with an Alzheimer s drug GM-CSF, which has pro-inflammatory, anti-inflammatory and immune regulatory properties, reverses learning and memory deficits, the loss of certain nerve cells, and other abnormalities in the brain in a mouse model of Down syndrome.